Theoretical risk of genetic reassortment should not impede development of live, attenuated Rift Valley fever (RVF) vaccines commentary on the draft WHO RVF Target Product Profile

Theoretical risk of genetic reassortment should not impede development of live, attenuated Rift Valley fever (RVF) vaccines commentary on the draft WHO RVF Target Product Profile

In November 2019, The World Health Organization (WHO) issued a draft set of Target Product Profiles (TPPs) describing optimal and minimally acceptable targets for vaccines against Rift Valley fever (RVF), a Phlebovirus with a three segmented genome, in both humans and ruminants. The TPPs contained r...

Full description

Bibliographic Details
Main Authors: Thomas P. Monath, Jeroen Kortekaas, Douglas M. Watts, Rebecca C. Christofferson, Angelle Desiree LaBeaud, Brian B Gowen, Clarence J. Peters, Darci R. Smith, Robert Swanepoel, John C. Morrill, Thomas G. Ksiazek, Phillip R Pittman, Stuart T. Nichol, Brian H. Bird, George Bettinger
Format: Article
Language:English
Published: Elsevier 2020-08-01
Series:Vaccine: X
Subjects:
Rift Valley Fever vaccine
Target Product Profile
Genetic reassortment
Online Access:http://www.sciencedirect.com/science/article/pii/S2590136220300073

Internet

http://www.sciencedirect.com/science/article/pii/S2590136220300073

Similar Items